FY2025 · ended Dec 31, 2025 · Revenue $780.57M, +23.6% YoY · Filed Feb 26, 2026
Collegium Pharmaceutical, Inc. (COLL) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $780.6 million and net income of $62.9 million. Free cash flow was $327.6 million. As of Sep 30, 2026 it held $144.8 million in cash and investments and $5.5 million in total debt.
Revenue (TTM)
$815.19M
+7.7% vs year-ago TTM
Net income (TTM)
$38.17M
-34.7% vs year-ago TTM
Operating cash flow (TTM)
$338.02M
+16.2% vs year-ago TTM
Free cash flow (TTM)
$336.29M
+16.2% vs year-ago TTM
EPS (TTM)
$1.09
-26.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
31.75M
+0.9% vs prior year
Net cash
$139.29M
as of Sep 30, 2026
Operating margin
15.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COLL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- VA
- Headquarters
- Stoughton, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1267565
- Former names
- COLLEGIUM PHARMACEUTICAL INC (until Mar 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M | $276.9M |
| Operating income | $179.6M | $169.9M | $167.0M | $33.3M | $17.6M |
| Net income | $62.9M | $69.2M | $48.2M | -$25.0M | $71.5M |
| Diluted EPS | $1.73 | $1.86 | $1.29 | -$0.74 | $1.86 |
| Operating cash flow | $329.3M | $205.0M | $274.7M | $124.2M | $103.6M |
| Free cash flow | $327.6M | $203.3M | $274.3M | $122.6M | $101.6M |
| Total assets | $1.7B | $1.7B | $1.1B | $1.2B | $692.1M |
| Total liabilities | $1.4B | $1.4B | $947.9M | $979.3M | $489.1M |
| Stockholders' equity | $301.7M | $228.8M | $195.4M | $194.8M | $202.9M |
| Cash and investments | $386.7M | $162.8M | $310.5M | $173.7M | $186.4M |
| Total debt | $5.5M | $6.8M | $7.1M | $8.2M | $8.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Agreement ended
|
Oct 19, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Aug 13, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
All 870 Collegium Pharmaceutical, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.